StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

Akebia Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Akebia Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $70.46M, up 71.7% year over year. For fiscal 2025 it was $62.36M, up 65.6% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $322.97M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$62.36M+65.6%
FY2024Dec 31, 2024$37.65M-40.3%
FY2023Dec 31, 2023$63.08M-51.5%
FY2022Dec 31, 2022$129.99M-12.1%
FY2021Dec 31, 2021$147.85M-32.3%
FY2020Dec 31, 2020$218.49M-32.4%
FY2019Dec 31, 2019$322.97M+11.0%
FY2018Dec 31, 2018$291.01M+26.0%
FY2017Dec 31, 2017$230.89M+99.4%
FY2016Dec 31, 2016$115.79M+169.2%
FY2015Dec 31, 2015$43.02M+84.9%
FY2014Dec 31, 2014$23.26M+161.3%
FY2013Dec 31, 2013$8.90M+58.1%
FY2012Dec 31, 2012$5.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.06M+27.7%
Q1 FY2026Mar 31, 2026$14.81M+51.8%
Q4 FY2025Dec 31, 2025$26.65M+126.1%
Q3 FY2025Sep 30, 2025$14.94M+76.1%
Q2 FY2025Jun 30, 2025$11.01M+44.0%
Q1 FY2025Mar 31, 2025$9.75M+0.2%
Q4 FY2024Dec 31, 2024$11.79M+19.5%
Q3 FY2024Sep 30, 2024$8.49M-36.3%
Q2 FY2024Jun 30, 2024$7.65M-62.1%
Q1 FY2024Mar 31, 2024$9.73M-50.6%
Q4 FY2023Dec 31, 2023$9.87M-69.3%
Q3 FY2023Sep 30, 2023$13.33M-52.4%
Q2 FY2023Jun 30, 2023$20.20M-22.4%
Q1 FY2023Mar 31, 2023$19.69M-55.1%
Q4 FY2022Dec 31, 2022$32.10M+8.6%
Q3 FY2022Sep 30, 2022$28.03M-30.7%
Q2 FY2022Jun 30, 2022$26.03M-30.1%
Q1 FY2022Mar 31, 2022$43.83M+7.9%
Q4 FY2021Dec 31, 2021$29.56M-21.3%
Q3 FY2021Sep 30, 2021$40.47M-13.6%
Q2 FY2021Jun 30, 2021$37.21M-29.5%
Q1 FY2021Mar 31, 2021$40.61M-50.0%
Q4 FY2020Dec 31, 2020$37.58M-53.3%
Q3 FY2020Sep 30, 2020$46.86M-37.1%
Q2 FY2020Jun 30, 2020$52.82M-38.4%
Q1 FY2020Mar 31, 2020$81.23M-1.4%
Q4 FY2019Dec 31, 2019$80.41M-7.6%
Q3 FY2019Sep 30, 2019$74.51M+5.5%
Q2 FY2019Jun 30, 2019$85.69M+19.2%
Q1 FY2019Mar 31, 2019$82.35M+34.1%
Q4 FY2018Dec 31, 2018$87.05M+27.3%
Q3 FY2018Sep 30, 2018$70.63M+20.3%
Q2 FY2018Jun 30, 2018$71.92M+64.4%
Q1 FY2018Mar 31, 2018$61.40M+2.3%
Q4 FY2017Dec 31, 2017$68.38M+104.5%
Q3 FY2017Sep 30, 2017$58.71M+87.9%
Q2 FY2017Jun 30, 2017$43.75M–
Q1 FY2017Mar 31, 2017$60.05M–
Q4 FY2016Dec 31, 2016$33.44M–
Q3 FY2016Sep 30, 2016$31.24M–

More Akebia Therapeutics figures

See a number that looks wrong?